APRO家族基因在胃癌中的表达及预后意义

Expression and Prognostic Value of APRO Family in Gastric Cancer

目的:基于大数据挖掘分析BTG/Tob抗增殖蛋白家族(anti-proliferativeprotein family,APRO)基因在胃癌组织的表达及其对胃癌患者预后的影响。方法:采用Oncomine数据库分析APRO家族6个成员在胃癌组织中的m RNA表达情况,通过Kaplan-Meier Plotter数据库进行胃癌患者总生存期的分析。结果:相比正常胃组织,BTG2在胃癌组织中呈低表达;BTG3在肠型胃癌组织中呈高表达,而在总体胃癌组织中呈低表达。BTG3低表达的患者总生存期较短;对5-氟尿嘧啶辅助化疗的胃癌患者,低表达BTG2的预后较差。结论:BTG2、BTG3的m RNA表达在胃癌和正常胃组织中有明显差异。BTG3低表达的胃癌患者预后较差;BTG2可能参与调节胃癌患者5-氟尿嘧啶治疗的敏感性。

Objective： To analyze the expression and prognostic value of BTG/Tob anti-proliferative（APRO） protein family in gastric cancer based on big data mining. Methods： The m RNA expression levels of six members of this family in gastric cancer tissues were analyzed via the Oncomine database. Moreover, the Kaplan-Meier database was used to evaluate the effect on overall survival（OS）of patients with gastric cancer. Results： Compared with the normal gastric tissue, BTG2 expression was lower in gastric cancer tissue,BTG3 expression was upregulated in intestinal gastric cancer tissue, but downregulated in total gastric cancer tissue. Patients with lower BTG3 expression had a shorter overall survival; gastric cancer patients with 5-fluorouracil based adjuvant chemotherapy had a worse prognosis in low BTG2 expression group. Conclusions： m RNA expression of BTG2 and BTG3 in gastric cancer and normal gastric tissues were significantly different. Patients with lower BTG3 expression had a poor prognosis. In addition, BTG2 may be involved in the sensitivity of 5-fluorouracil based adjuvant chemotherapy in gastric cancer patients.